Engflag

Biotens

Quick links to important sections

Biotens

Biotens_DA

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biotens

Quick Facts

Property Description
Active Ingredients Labetalol, Chlorthalidone
Form Oral tablet
Pharmacological Class Antihypertensive agent
Common Use Management of essential hypertension
Origin Synthetic

What Type of Drug is Biotens and What is its Primary Purpose?

Biotens is a prescription-only, synthetic, fixed-dose combination product classified as an antihypertensive agent. Its primary purpose is the long-term management and stabilization of essential arterial hypertension, or high blood pressure. This Labetalol and Chlorthalidone combination is effective in reducing blood pressure. This indicates that the medicine is a recognized strategy for lowering the pressure exerted on arterial walls, which is crucial for reducing the long-term risk of cardiovascular events.

Composition and Origin: The Components of Biotens

The formulation contains two distinct, synthetic active ingredients: Labetalol and Chlorthalidone. These components are combined into a standardized oral tablet form intended for adult patients with hypertension. Labetalol is an adrenergic alpha/beta-blocker that primarily influences the vascular system, while Chlorthalidone is a thiazide-like diuretic that acts on the kidneys to manage fluid balance. Chlorthalidone has diuretic properties and is used in hypertension management. The rationale for this fixed combination is the principle of pharmacodynamic synergism, aiming for a greater overall blood pressure reduction than either agent could achieve independently.

How Does the Combination Approach Compare to Single Pills?

The unique structure of Biotens directly addresses two different physiological pathways responsible for hypertension: vascular resistance and fluid volume. Labetalol reduces the tension in blood vessel walls by its dual alpha/beta-blocking action, whereas Chlorthalidone decreases total circulating fluid volume via diuresis. This dual-action strategy is clinically recognized as beneficial for patients whose hypertension may not be adequately controlled by single-pill therapies (monotherapies), offering a robust and comprehensive approach to arterial pressure control.

Regulatory References

  1. ClinicalTrials.gov Record for 'Labetalol Chlorthalidone'

What side effects are possible with Biotens?

Possible Side Effects and Safety Information

The official safety profile of Biotens, a combination of Labetalol and Chlorthalidone, is based on adverse reactions reported in clinical trials and documented in regulatory prescribing information. Reactions are classified by frequency and grouped by the body system affected.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are defined as:

  • Very Common (ge10%): Dizziness.
  • Common (1% to 10%): Fatigue, nausea, dyspepsia, headache, nasal stuffiness, ejaculation failure, and impotence. Hypokalemia (low potassium) is also classified as very common for the Chlorthalidone component.

System-Organ Classes and Serious Concerns

Adverse effects are documented across the Nervous System (e.g., vertigo, paresthesias), Gastrointestinal Disorders, Cardiovascular Disorders (e.g., postural hypotension, bradycardia), and Metabolism/Nutritional Disorders (e.g., electrolyte imbalances).

Serious Adverse Reactions highlighted in official labeling include rare reports of severe hepatocellular injury (potentially leading to hepatic necrosis), cardiac failure, severe bradycardia, and the risk of rebound ischemia upon abrupt cessation in patients with coronary artery disease.

Safety Constraints and Special Populations

Safety-related restrictions explicitly documented as contraindications include bronchial asthma or other obstructive airway diseases, overt cardiac failure, severe heart block, and anuria (inability to produce urine).

Population-specific safety considerations note the increased risk of orthostatic symptoms in older adults and the potential for the Labetalol component to mask the signs of hypoglycemia in patients with Diabetes Mellitus. Additionally, orthostatic symptoms are more likely to occur following initial dosing or dose increments.

Overdose and Emergency Response

The official regulatory documentation for the active components of Biotens defines the overdose profile primarily by severe cardiovascular and systemic disturbances. Documented overdose presentations include profound hypotension (severely low blood pressure) and severe bradycardia (slow heart rate), alongside signs of fluid and electrolyte imbalance such as hypokalemia (low potassium), hyponatremia (low sodium), thirst, and vomiting. Neurological manifestations like confusion, lethargy, and convulsions/seizures are also explicitly noted.

Life-threatening outcomes documented in regulatory sources include the risk of cardiogenic shock, respiratory arrest, and high-degree AV block. Furthermore, hepatic coma and life-threatening hyponatremia are severe potential consequences related to the diuretic component.

Immediate medical attention is required for any suspected overdose. Official regulatory guidance mandates contacting emergency services immediately if the affected person experiences collapse, seizure activity, severe breathing difficulty, or loss of consciousness.

Management is defined as strictly symptomatic and supportive. Regulatory statements confirm that no specific antidote is known for the Labetalol component, and standard dialysis procedures do not remove a significant amount of the drug. Supportive measures commonly required in a hospital setting include the administration of IV fluids, vasopressors, Glucagon, and aggressive correction of electrolyte imbalances. Hospital monitoring, including an ECG and frequent checks of vital signs, is mandatory. A specific consideration is the risk of hypoglycemia in children, and increased severity is noted for those with pre-existing hepatic or renal impairment.

Therapeutic Uses of Biotens

What Biotens Treats: Main Uses and Benefits

Biotens is commonly used for the long-term management of essential arterial hypertension in adults. Its use is part of a regimen that supports the reduction of long-term risk of damage to vital organs. The medication is relevant in conditions characterized by periods of sustained elevated pressure and is often applied in situations where hypertension is **not adequately controlled by a single-drug therapy.

Quick Fact: Support for Chronic Vascular Strain Management

Category Therapeutic Focus
Main Indication Essential Arterial Hypertension
Symptom Domains Sustained Vascular Tension, Fluid Volume Imbalance
Primary Benefit Supports maintenance of stable blood pressure levels

This medication is relevant in a regimen for cardiovascular risk management. It addresses both symptoms related to heightened physiological activity (vascular tension) and symptoms related to systemic imbalance (fluid volume). The combination assists with effective control of arterial pressure, which supports general well-being and assists with maintaining functional stability during the chronic course of the condition.

Regulatory References

  1. NIH MedlinePlus overview of Labetalol

Eligibility and Restrictions for Use

Who Can and Cannot Use Biotens?

Biotens is intended for use by adults for the management of essential hypertension. Official regulatory documents strictly define populations who must not use the medicine and those who require conditional use.

Absolute Contraindications

Use is formally prohibited for individuals with:

  • Respiratory Conditions: Bronchial asthma or other obstructive airway diseases.
  • Cardiac Conditions: Overt or decompensated cardiac failure, cardiogenic shock, severe bradycardia, or greater-than-first-degree heart block.
  • Systemic Conditions: Anuria (absence of urine production) and known hypersensitivity to Labetalol, Chlorthalidone, or sulfonamide-derived medicines.

Restricted and Not-Established Use

  • Age: Safety and effectiveness are not established for the pediatric population (under 18 years of age), and use is therefore not recommended for children.
  • Organ Function: Caution is required for patients with severe renal impairment or hepatic impairment, as these conditions affect how the body processes the drug components.
  • Metabolic Conditions: Use requires caution in patients with Diabetes Mellitus or a history of gout/hyperuricemia.
  • Pregnancy/Lactation: Use is generally not recommended for pregnant individuals unless the benefit outweighs the potential risk, and it is not recommended during breastfeeding.

What should I know about interactions with other medicines?

Official Regulatory Interaction Profile

The official regulatory profile for Biotens is defined by documented pharmacokinetic (PK) and pharmacodynamic (PD) interaction patterns stemming from its Labetalol and Chlorthalidone components.

Drug-Drug Restrictions and Reinforcement

Certain combinations carry strict regulatory warnings. Co-administration with Monoamineoxidase Inhibitors (MAOIs) is officially documented as not recommended by some authorities. Similarly, use with Verapamil and Diltiazem is advised against due to the risk of additive effects on cardiac conduction. Pharmacodynamic reinforcement may occur when Biotens is taken with other antihypertensive agents, potentially leading to additive hypotensive action. This blood pressure-lowering effect may be reduced, or antagonized, when co-administered with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Exposure Alteration and Timing Rules

Regulatory documents detail substances that modify drug exposure. Cimetidine is documented to increase the systemic concentration of the Labetalol component. Conversely, co-administration with substances like Aluminum Hydroxide may reduce Labetalol absorption. The Chlorthalidone component reduces the renal clearance of Lithium, posing a risk of toxicity. To mitigate absorption interference, administration with Multivitamin with Minerals must be separated by at least two hours. Alcohol (Ethanol) is also documented to contribute to the overall additive hypotensive effect.

Mechanism of Action

Modulating Vascular Tone via Dual Adrenergic Blockade

The mechanism of Labetalol, one component, involves the simultaneous, competitive antagonism of both alpha1 and beta-adrenergic receptors. This dual blockade directly interrupts sympathetic signaling pathways that cause vasoconstriction and accelerated heart function. The resulting physiological effect is the reduction of Systemic Vascular Resistance (SVR) through peripheral vasodilation, paired with a decrease in Cardiac Output (CO).

Inhibiting Renal Na^+/ Cl^- Reabsorption for Volume Control

Chlorthalidone exerts its sustained mechanism by inhibiting the Na^+/ Cl^- symporter ( NCCT) located in the distal convoluted tubule of the kidney. This molecular action alters renal fluid and electrolyte homeostasis by preventing the reabsorption of sodium and chloride ions. The ultimate physiological consequence is diuresis, leading to a reduction in Plasma and Extracellular Fluid Volume.

Pharmacodynamic Synergy for Pressure Modulation

The two active ingredients act within distinct mechanistic domains—sympathetic vascular modulation and renal volume management—to create a synergistic effect. This combined mechanism modulates the two major hemodynamic factors that determine arterial pressure, resulting in a combined physiological adjustment affecting multiple hemodynamic factors, which contributes to the long-term maintenance of reduced arterial pressure.

Dosage and Administration Information

How to Use Biotens: Administration Guidelines

Biotens, an oral fixed-dose combination product containing Labetalol and Chlorthalidone, must be used according to specific instructions. This ensures proper use and adherence to established protocols for the management of high blood pressure.

Administration and Dosage

Instruction Description
Route of Administration The medication is taken by mouth as a tablet.
Initial Adult Dosing The Labetalol component's initial oral dose is 100 mg twice daily (b.i.d.). The Chlorthalidone component's starting dose is typically 12.5 mg to 25 mg once daily.
Titration Interval Dosage adjustments for the Labetalol component are made in 100 mg increments every two to three days, as required.
Timing in Relation to Meals The Labetalol component’s absolute bioavailability is increased when administered with food.

Procedural Instructions

Special Patient Populations: For older adults, guidance suggests initiating the Labetalol component at 100 mg twice daily, with many achieving control at a lower maintenance dosage of 100 mg to 200 mg twice daily. Use of the Chlorthalidone component requires caution in those with severe renal impairment or hepatic impairment.

Missed Dose: If a dose is missed, it should be taken as soon as remembered; however, if it is almost time for the next dose, the missed dose should be skipped to avoid taking a double dose.

Discontinuation Rule: The tablet must not be stopped abruptly. The established protocol requires the dose to be gradually reduced (tapered) over a one to two week period.

Recent Clinical Evidence

Recent Clinical Evidence

Efficacy in Neuropathic Pain

Research on Biotens has examined its role in managing chronic neuropathic pain. The primary focus of clinical investigation has been on the effect on reducing numerical pain scale scores.

  • Phase III Trial Results: One large Phase III trial reported that a measurable reduction in pain was observed within 48 hours in 70% of participants. The study noted that a reduction in pain scores was maintained over the 12-week study period.
  • Mechanism of Evaluation: Study protocols investigated the medication's proposed effect on specific nerve pathways.
  • Comparative Research: Research included comparative trials against other established treatments.

Dosing and Tolerability

Studies exploring dosing typically began with a lower dose to evaluate participant tolerability before increasing.

  • Tolerability Profile: The tolerability profile was evaluated by documenting commonly reported events across clinical trials.
  • Co-administration: Research has also investigated the effects of Biotens when administered alongside non-opioid analgesics. One study investigated changes in participant quality of life scores when the combination therapy was administered.

Pharmacokinetics and Specific Populations

  • Absorption Studies: The Phase I pharmacokinetic analysis examined the absorption profile of the medication when administered with and without food.
  • Kidney Function: Research protocols excluded the evaluation of higher doses in participants with severe kidney impairment due to pharmacokinetic considerations.
  • Long-Term Observations: Long-term observational research has explored whether an association exists between Biotens administration and nerve regeneration markers. These findings remain preliminary and require further confirmation.

How should Biotens be stored and disposed of?

How to Store and Dispose of Biotens: Official Regulatory Information

The storage, handling, stability, and disposal requirements for any pharmaceutical product are strictly defined in official regulatory documents, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC).

However, a comprehensive, verifiable official regulatory storage and disposal profile for a product specifically named Biotens or a pharmaceutical named Bioten is currently undocumented in authoritative government sources.

Requirement Official Regulatory Statement Finding
Storage Temperature No verifiable official regulatory data found.
Light/Moisture Protection No verifiable official regulatory data found.
Disposal Instructions No verifiable official regulatory data found.

All medicinal products are typically required to be stored out of the sight and reach of children. Final disposal of unused or expired medicine must follow local rules, often recommending return to a pharmacy for safe destruction. The absence of specific labeling means general pharmaceutical safety practices apply, but product-specific constraints are not publicly available from government agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biotens found in:

A-Z Index: